Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia  Date: 2021-04-06

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical trials displayed promising outcome.

The pharmaceutical firm said that in its Phase 3 trials, more than 91.15% of patients administered with PegIFN PegiHepTM, had an RT-PCR negative result by the seventh day, in comparison to 78.90% of patients treated with SOC (standard of care) arm.

In the case of moderate COVID-19 patients, the medication decreased the period of additional oxygen from 84 hours to 56 hours. This shows that it was able to manage respiratory distress and failure, which has been one of the most difficult aspects of managing COVID-19, the company added.

It is worth noting that the drug has a well-established record of safety, with several doses being given to chronic hepatitis B and C patients for several years.

Aging decreases the ability of the body to generate Interferon Alpha which helps in responding to viral infections, further increasing the risk of death among elderly individuals. Pegylated Interferon Alpha 2b, provided at an early stage of the infection, can compensate for this deficiency and speed up recovery.

The preliminary findings suggest that, if given early, PegIFN can help in faster recovery of patients and prevent many of the problems seen in later stages of the disease. Since it is a single-dose regimen, the treatment would be less difficult and more affordable, Zydus said.

Dr. Sharvil Patel, Managing Director at Cadila Healthcare Ltd., reportedly said that they are motivated by the Phase III results of the PegIFN study which has shown the potential to decrease the impact of the virus when given in the early stage of the disease.

In addition to performing a Phase-II trial in Mexico, the company is collaborating with the USFDA on Pegylated Interferon clinical trials in the United States, sources with relevant information cited.

Source Credit –

https://www.businesstoday.in/current/corporate/zydus-covid-19-drug-shows-promise-phase-3-trials-seeks-dcgi-nod/story/435729.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

CI NMF, Amp Energy India to jointly invest USD 200 Mn in renewables

CI NMF, Amp Energy India to jointly invest USD 200 Mn in renewables

By Nikita Chaurasia

Copenhagen Infrastructure Partners, one of the biggest renewable energy-centered fund managers worldwide, has signed an agreement with Amp Energy India Pvt Ltd. for joint equity investments of USD 200 million in renewables, using its Copenhagen Infra...

CDC updates guidelines, calls for vaccinated people to mask up

CDC updates guidelines, calls for vaccinated people to mask up

By Nikita Chaurasia

The Centers for Disease Control and Prevention issued new guidelines suggesting that people who are vaccinated against Covid-19 wear masks in public as well as indoor areas where the rate of the disease is high. The CDC also stated that teachers, sta...

iPhone’s hot streak could be hampered by global chip shortage crisis

iPhone’s hot streak could be hampered by global chip shortage crisis

By Nikita Chaurasia

Apple Inc. recently stated that the global chip shortage that has affected the sales of Macs and iPads, will now hit iPhone production and the expected revenue growth is likely to decelerate. This has resulted in lowering Apple’s shares. The c...

EV maker Rivian bags USD 2.5 Bn in a funding round led by Amazon, Ford

EV maker Rivian bags USD 2.5 Bn in a funding round led by Amazon, Ford

By Nikita Chaurasia

American electric vehicle maker Rivian Automotive LLC reportedly secured USD 2.5 billion in a funding round led by Amazon.com Inc, T. Rowe Price, D1 Capital Partners, and Ford Motor Co. In addition, the event also saw participation from Fidelity Man...

ICEA forms committee chaired by HP India MD to boost IT hardware sector

ICEA forms committee chaired by HP India MD to boost IT hardware sector

By Nikita Chaurasia

The India Cellular & Electronics Association (ICEA) recently announced the formation of a committee to promote manufacturing and exports of the IT hardware sector. The panel headed by Ketan Patel, HP India’s Managing Director, will set up a...